Our Passion, Your Health.

2016

7 December 2016

Gel Featuring Hyaluronic Acid Offers Long-Lasting Hydration to Women With Vaginal Dryness

FIDIA PHARMA USA INC. Introduces New Product Packaging for HYALO GYN® Featuring a Fresh, Feminine Look
PARSIPPANY, N.J., Dec. 7, 2016 – Many women suffer silently from the bothersome symptoms associated with vaginal dryness. Vaginal dryness can have many origins, including childbirth, breast-feeding, menopause, chemotherapy, oral contraceptive use and stress.1 Vaginal hydrating gels, such as HYALO

28 November 2016

FIDIA PHARMA USA INC. Introduces New Product Packaging for HYALO GYN® Featuring a Fresh, Feminine Look

PARSIPPANY, N.J., Nov. 28, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA INC., introduces newly redesigned packaging for the vaginal hydrating gel, HYALO GYN®. While keeping its current formulation, HYALO GYN®’s new product packaging gives the

10 November 2016

HYMOVIS® Receives Permanent, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)

PARSIPPANY, NJ.(BUSINESS WIRE)— Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services ("CMS") has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System ("HCPCS") code, or J-Code.

5 July 2016

Fidia Presents New Data on HYMOVIS® , a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting

HYMOVIS® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis® in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented.
PARSIPPANY, N.J., July 5, 2016 – Fidia Farmaceutici S.p.A., a world leader

12 May 2016

Fidia Announces US Commercial Availability of Hymovis®, a Next-Generation Hyaluronan

A breakthrough in viscoelastic technology; Hymovis® is an excellent choice for the high-demand patient with OA of the knee
PARSIPPANY, N.J., May 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., announced that Hymovis® (high molecular weight

25 February 2016

Fidia Introduces Hymovis®, a Next-Generation Hyaluronan, at the AAOS Annual Meeting in Orlando

Hymovis®, which is being launched in the U.S, is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties
PARSIPPANY, N.J., February 25, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness